Ionis PharmaceuticalsIONS
IONS
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
16% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 50
2.66% more ownership
Funds ownership: 98.97% [Q3] → 101.63% (+2.66%) [Q4]
1% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 118
0% more funds holding
Funds holding: 349 [Q3] → 349 (+0) [Q4]
10% less capital invested
Capital invested by funds: $6.24B [Q3] → $5.61B (-$633M) [Q4]
15% less call options, than puts
Call options by funds: $26.1M | Put options by funds: $30.5M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$39
43%
upside
Avg. target
$54
97%
upside
High target
$70
157%
upside
6 analyst ratings
3 positive
50%
3 neutral
50%
0 negative
0%
Redburn Atlantic Joshua Smith 50% 1-year accuracy 1 / 2 met price target | 43%upside $39 | Neutral Initiated | 31 Mar 2025 |
JP Morgan Jessica Fye 69% 1-year accuracy 27 / 39 met price target | 65%upside $45 | Neutral Maintained | 24 Mar 2025 |
Citigroup David Lebowitz 32% 1-year accuracy 6 / 19 met price target | 135%upside $64 | Buy Maintained | 20 Feb 2025 |
RBC Capital Luca Issi 22% 1-year accuracy 12 / 55 met price target | 157%upside $70 | Outperform Reiterated | 20 Feb 2025 |
BMO Capital Kostas Biliouris 16% 1-year accuracy 3 / 19 met price target | 65%upside $45 | Market Perform Maintained | 20 Feb 2025 |
Financial journalist opinion
Based on 7 articles about IONS published over the past 30 days
Neutral
Business Wire
1 day ago
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 Bank of America 2025 Health Care Conference on Wednesday, May 14, 2025 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025 A live webcast of these presentations can be accessed on the Investors & Media secti.
Positive
Zacks Investment Research
5 days ago
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
In return, Ionis will receive an undisclosed upfront payment from Sobi. It is also eligible to receive milestone payments and a tiered royalty on the drug's future sales.
Neutral
Business Wire
6 days ago
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® receives exclusive rights in countries outside the U.S., Canada and China to commercialize olezarsen as a potential treatment for familial chylomicronemia syndrome (FCS) and severely elevated triglycerides. Ionis will continue to independently commercialize olezarsen in the U.S. Olezarsen was approved by the FDA in December 2024 under the t.
Positive
Zacks Investment Research
1 week ago
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Neutral
Business Wire
2 weeks ago
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it has entered into a license agreement with Ionis Pharmaceuticals, Inc. (Carlsbad, CA,U.S.; CEO, Brett P. Monia, Ph.D.; “Ionis”) for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Sapablursen is currently being evaluated in adult patients with PV in the fully enrolled Phase 2 IMPRSSION study. Sapablu.
Neutral
Business Wire
2 weeks ago
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease. Sapablursen is currently being evaluated in adults living.
Neutral
Business Wire
3 weeks ago
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.
Neutral
Business Wire
1 month ago
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 U.
Positive
Zacks Investment Research
1 month ago
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
IONS reports better-than-expected top and bottom-line numbers for the fourth quarter.
Neutral
Business Wire
1 month ago
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension (OLE) study of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Results will be presented at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organiz.
Charts implemented using Lightweight Charts™